Illumina (NASDAQ:ILMN) Issues FY 2025 Earnings Guidance

Illumina (NASDAQ:ILMN) updated its FY 2025 earnings guidance on Monday. The company provided EPS guidance of 4.500-4.500 for the period, compared to the consensus EPS estimate of 4.510. The company issued revenue guidance of -. Illumina also updated its FY25 guidance to $4.50 EPS.

Analyst Ratings Changes

Several equities research analysts have recently commented on the company. Citigroup decreased their price target on Illumina from $130.00 to $90.00 and set a “neutral” rating on the stock in a research note on Tuesday, March 4th. Stephens upped their target price on Illumina from $170.00 to $184.00 and gave the company an “overweight” rating in a research note on Tuesday, November 12th. Canaccord Genuity Group reduced their target price on Illumina from $145.00 to $135.00 and set a “hold” rating on the stock in a research note on Friday, February 7th. TD Cowen lowered Illumina from a “buy” rating to a “hold” rating and reduced their target price for the company from $177.00 to $140.00 in a research note on Friday, February 7th. Finally, Barclays lowered Illumina from an “equal weight” rating to an “underweight” rating and reduced their target price for the company from $130.00 to $100.00 in a research note on Monday, February 10th. One equities research analyst has rated the stock with a sell rating, ten have given a hold rating, ten have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $149.25.

Illumina Stock Performance

Shares of ILMN stock opened at $85.97 on Tuesday. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.42 and a current ratio of 1.77. Illumina has a one year low of $80.18 and a one year high of $156.66. The company’s 50-day simple moving average is $117.43 and its 200-day simple moving average is $131.17. The stock has a market capitalization of $13.62 billion, a price-to-earnings ratio of -11.19, a PEG ratio of 1.60 and a beta of 1.17.

Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Thursday, February 6th. The life sciences company reported $0.86 earnings per share for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. Equities analysts anticipate that Illumina will post 4.51 earnings per share for the current fiscal year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.